Tag: Singapore eDevelopment
Impact Biomedical Achieves COVID-19 Success with Equivir and 3F Biofragrance
Singapore eDevelopment Limited's (SeD; SGX:40V) wholly owned subsidiary Impact Biomedical Inc. has announced proven in vitro success with Equivir and 3F Biofragrance...
Impact Biomedical’s Majority Owned Next Generation Medical Technologies Valued at USD...
SGX-listed Singapore eDevelopment Ltd's (SeD; SGX:40V) wholly owned subsidiary Impact Biomedical Inc., announced today that their suite of antiviral and medical technologies,...
Impact BioMedical’s Linebacker and Equivir inhibit SARS-CoV-2, virus responsible for the...
Both compounds block integral viral mechanisms for SARS-CoV-2 replication and infection
SGX-listed Singapore eDevelopment...
New Method to Prevent and Treat Tuberculosis
SGX-listed Singapore eDevelopment Limited ("SeD", SGX:40V) wishes to announce that its biomedical subsidiary incorporated in Nevada, Global BioLife Inc. ("Global BioLife") will...
